Vivani Medical announced an update on its definitive merger agreement with ClearOne, Inc., via its subsidiary Cortigent. The company anticipates the pricing and closing of this transaction will occur in October 2026. Vivani Medical operates in the medical device industry.

Vivani Medical announced the successful dosing of all participants in its SLIM-1 Phase 1 clinical trial for NPM-139, a miniature subdermal semaglutide implant designed for chronic weight management. The trial enrolled 20 GLP-1 naïve participants in Australia, with initial dosing completed ahead of schedule on July 29 and the remaining participants dosed one week later without issues. Top-line data regarding safety, tolerability, and pharmacokinetics is expected in November 2026. This milestone follows a July 2026 agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal technology. The company anticipates initiating a Phase 2 dose-ranging trial in 2027 based on these results. Vivani Medical operates in the biopharmaceutical industry, developing miniature implants for extended drug delivery.

Vivani Medical, Inc. presented at the Emerging Growth Conference in New York on July 15, 2026. During the presentation, CEO Dr. Adam Mendelsohn provided an update stating that the first dosing of the company's SLIM-1 is expected to occur in August 2026. Vivani Medical, Inc. is a biotechnology company focused on developing medical treatments.

Vivani Medical, Inc. entered into a definitive merger agreement on July 1, 2026, where its subsidiary Cortigent, Inc. will merge into a ClearOne, Inc. subsidiary, making Cortigent a wholly owned subsidiary of ClearOne. Vivani will receive 12,500,000 shares of ClearOne common stock as consideration. As a condition to closing, ClearOne will raise between $10,000,000 and $15,000,000 through a financing unit issuance. Vivani Medical, Inc. is a medical technology company focused on its NanoPortal platform technology for drug delivery systems.

Vivani Medical, Inc. stockholders' 2thought: 2026 Annual Meeting results show the approval of the 2022 Amended Plan, which increases the number of shares reserved under the plan by 11,000,000 to a total of 21,033,333 shares. Additionally, the company received regulatory approval from Bellberry in Australia to initiate a Phase 1 clinical trial of NPM-139, a semaglutide implant. Vivani Medical, Inc. is a medical technology company focused on drug delivery systems.